PeptiDream (4587) Q4 2025 earnings summary

Executive summary

• Transitioned from a discovery-focused start-up to a global pharmaceutical company with a robust pipeline in macrocyclic peptide therapeutics and radiopharmaceuticals, ending FY2025 with 13 clinical programs, nearly doubling from the previous year.

• Maintained profitability in radiopharmaceuticals for the fourth consecutive year, but overall FY2025 revenue was significantly below forecast due to delayed out-licensing and milestone deals, resulting in a net loss of ¥3.7 billion.

• Management structure expanded and major investments initiated in R&D and manufacturing facilities to support future growth.

• No dividends paid or planned, with a focus on R&D investment and internal reserves.

Financial highlights

• FY2025 revenue was ¥18.5 billion, down 60.3% YoY and significantly below the initial forecast, mainly due to delayed out-licensing; radiopharmaceuticals contributed ¥15.7 billion, drug discovery ¥2.8 billion.

• EBITDA was negative at ¥2.8 billion; net loss attributable to owners was ¥3.7 billion; basic EPS was -¥28.99.

• Cash and cash equivalents ended at ¥28.7 billion, down ¥19.4 billion YoY.

• R&D expenses to increase from ¥5 billion in 2025 to ¥6.5 billion in 2026.

• FY2026 revenue forecast is ¥32 billion plus potential large upfront payments, with core operating profit expected at ¥4.6 billion.

Outlook and guidance

• Anticipates 6–12 new clinical programs to enter development in 2026, targeting 19–25 programs by year-end.

• Conservative revenue guidance for 2026, separating high-probability projects (¥15 billion) from potential large lump-sum deals.

• Long-term goal to reach ¥100 billion in annual revenue, driven by core therapeutic areas.

• R&D spending and headcount expected to rise as more programs advance.